Mental health studies with practical context.

A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

This study has finished and is no longer accepting participants.

Recruitment status comes from the linked ClinicalTrials.gov record. Both registries list the identifiers for the same study.

Countries

United States, United Kingdom, Germany, + 2 others

Sponsor

Biogen Idec Research Limited

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 165)

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

United Kingdom, Czechia, Poland

Sponsor

Amgen Inc.

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 299)

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Italy, Spain

Sponsor

Amgen Inc.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Czechia, Hungary, + 2 others

Sponsor

ACADIA Pharmaceuticals Inc.

A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231 in Participants With Schizophreni...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria

Sponsor

Cerevel Therapeutics, LLC

A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 in Participants With Schizophreni...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Hungary

Sponsor

Cerevel Therapeutics, LLC

A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALK 3831, in Adults with Schizophrenia Treated with Olanzapine

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Czechia

Sponsor

Alkermes Inc.

A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects with Major Depressive Di...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

United Kingdom, Spain

Sponsor

Janssen-Cilag International NV

Safety study of GM-2505 in Depression

This study has finished and is no longer accepting participants.

Countries

United Kingdom

Sponsor

AbbVie

A Phase 2a, Multiple-Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti-Psychotic-Induced Extra-Pyramidal Symptoms Among Subjects Wi...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Germany

Sponsor

Schering-Plough Research Institute

A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Croatia, Latvia, + 1 other

Sponsor

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Study of BNC210 Tablet Formulation in Adults With PTSD (PTSD)

This study has finished and is no longer accepting participants.

Countries

United States, United Kingdom

Sponsor

Bionomics Limited